Analyst Ratings for Phathom Pharmaceuticals (PHAT)
PHAT Rating Summary
PHAT Price Target Summary
- Highest: $29.00 (Cantor Fitzgerald)
- Lowest: $10.00 (Leerink)
- Average: $21.67
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$21.67 (+213.1%)
* Over Last 12-Mos
Rating Score: 8.6 / 10
Percentile Rank: 87%
Avg. $ Target:
$21.67 (+213.1%)
* Over Last 12-Mos
Rating Score: 8.6 / 10
Percentile Rank: 87%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/9/2026 | Leerink | Daniel Clark | New Coverage | Market Perform (N/A) |
10.00 (N/A) |
9.43 (6.92) |
-26.62% | Details |
| 3/27/2026 | Barclays » Updated 8/17/2026 |
Glen Santangelo | Upgrade | Overweight (Equalweight) |
14.00 (18.00) |
10.47 (6.92) |
-33.91% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
